The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis

Bennett, D., Eckersall, P. D. , Waterston, M., Marchetti, V., Rota, A., Mcculloch, E. and Sbrana, S. (2013) The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis. BMC Veterinary Research, 9(42), (doi:10.1186/1746-6148-9-42)

[img]
Preview
Text
78423.pdf - Published Version
Available under License Creative Commons Attribution.

685kB

Publisher's URL: http://dx.doi.org/10.1186/1746-6148-9-42

Abstract

Background: Robenacoxib is a novel and highly selective inhibitor of COX-2 in dogs and cats and because of its acidic nature is regarded as being tissue-selective. Thirty four dogs with stifle osteoarthritis secondary to failure of the cranial cruciate ligament were recruited into this study. Lameness, radiographic features, synovial cytology and C-reactive protein concentrations in serum and synovial fluid were assessed before and 28 days after commencing a course of Robenacoxib at a dose of 1 mg/kg SID.<p></p> Results: There was a significant reduction in the lameness score (P <0.01) and an increase in the radiographic score (P < 0.05) between pre- and post-treatment assessments. There was no difference between pre- (median 1.49 mg/l; Q1-Q3 0.56-4.24 mg/L) and post – (1.10 mg/L; 0.31-1.78 mg/L) treatment serum C-reactive protein levels although synovial fluid levels were significantly reduced (pre- : 0.44 mg/L; 0.23-1.62 mg/L; post- : 0.17 mg/L; 0.05-0.49 mg/L) (P < 0.05). There was no correlation between C-reactive protein concentrations in serum and matched synovial fluid samples.<p></p> Conclusions: Robenacoxib proved effective in reducing lameness in dogs with failure of the cranial cruciate ligament and osteoarthritis of the stifle joint. The drug also reduced levels of C-reactive protein in the synovial fluid taken from the affected stifle joint. Robenacoxib appears to reduce articular inflammation as assessed by C-reactive protein which supports the concept that Robenacoxib is a tissue-selective non-steroidal anti-inflammatory drug.<p></p>

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Eckersall, Professor Peter and Waterston, Miss Mary and Bennett, Professor David and Mcculloch, Miss Eilidh
Authors: Bennett, D., Eckersall, P. D., Waterston, M., Marchetti, V., Rota, A., Mcculloch, E., and Sbrana, S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Biodiversity Animal Health and Comparative Medicine
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
College of Medical Veterinary and Life Sciences > School of Veterinary Medicine
Journal Name:BMC Veterinary Research
Publisher:BioMed Central Ltd
ISSN:1746-6148
Published Online:01 March 2013
Copyright Holders:Copyright © 2013 The Authors
First Published:First published in BMC Veterinary Research 9:42
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record